Clinical

Dataset Information

0

Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer


ABSTRACT: RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET imaging, may be effective in detecting residual disease after radiofrequency ablation of liver metastases in patients with colorectal cancer. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works for early detection of residual disease in patients undergoing radiofrequency ablation of liver metastases from colorectal cancer.

DISEASE(S): Neoplasm Metastasis,Colorectal Cancer,Colorectal Neoplasms,Metastatic Cancer

PROVIDER: 2041940 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2045806 | ecrin-mdr-crc
2013-01-18 | E-GEOD-43566 | biostudies-arrayexpress
| 2341429 | ecrin-mdr-crc
2022-07-27 | GSE180098 | GEO
2018-01-09 | GSE108853 | GEO
2022-09-16 | PXD036767 | iProX
| 2162342 | ecrin-mdr-crc
| 2020257 | ecrin-mdr-crc
| 2008036 | ecrin-mdr-crc
| 2188141 | ecrin-mdr-crc